Chronic opioid use and incident opioid use disorders in survivors of adolescent and young adult cancer after cancer treatment
Cancer · 2025
DOI: 10.1002/cncr.35866 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2025. Verfasst von Chun R Chao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA. Hauptthemen laut MEDLINE: Cancer Survivors, Opioid-Related Disorders, Neoplasms, Analgesics, Opioid. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Abstract (Originalsprache)
Background
The use of opioids and its benefits and harms among cancer survivors are poorly understood. The authors examined opioid use and related outcomes among adolescent and young adult (AYA) cancer survivors after cancer treatment.
Methods
The authors identified 2‐year cancer survivors diagnosed between 15 to 39 years of age at Kaiser Permanente Southern California (2000–2012, followed through 2019). Individuals without cancer were matched to survivors on age, sex, and calendar year for comparison. The authors used robust Poisson regression to compare long‐term (≥90 days) opioid use during follow‐up and Fine‐Gray hazard models to compare incident long‐term high‐dose use (≥50 morphine milligram equivalents daily dose ≥90 days), benzodiazepine co‐use, opioid use disorder (OUD), opioid overdose, and opioid‐related hospitalization. We also restricted analyses to individuals on long‐term opioid therapy, and evaluated risk factors for opioid‐related outcomes within cancer survivors.
Results
Of 5908 AYA cancer survivors and 81,833 noncancer individuals, 5.2% and 1.8% had long‐term opioid use during follow‐up, respectively (prevalence ratio = 1.8, 95% confidence interval, 1.6–2.0). Cancer survivors had higher incidence of long‐term high dose opioid use (hazard ratio [HR] = 2.2 [1.8–2.8]), benzodiazepine co‐use (HR = 1.4 [1.3–1.5]), and opioid‐related hospitalization (HR = 1.5 [1.1–2.2]) compared with noncancer individuals. Among those on long‐term opioid therapy, cancer survivors had elevated risk for long‐term high dose use (HR = 1.4 [1.1–1.8]) and benzodiazepine co‐use (HR = 1.6 [1.2–2.1]), but lower OUD risk (HR = 0.6 [0.4–0.9]). Opioid use during cancer treatment phase most strongly predicted long‐term high dose use and OUD/overdose during survivorship.
Conclusion
Findings call for risk‐stratified patient monitoring and better understanding of the differential OUD risk in AYA cancer survivors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California, USA.
- Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California, USA.
- Department of Geriatric, Palliative, and Continuing Care, Los Angeles Medical Center, Kaiser Permanente Southern California, Los Angeles, California, USA.
- Department of Pediatrics, City of Hope, Duarte, California, USA.
- MedHealth Statistical Consulting Inc, Sugarland, Texas, USA.
ORCID-Profile: Chun R Chao, Hui Zhou, Saro Armenian, Zheng Gu
Zitieren
APA
Chao, C. R., Zhou, H., Shalman, D. M., Pak, K. J., Armenian, S., Xu, L., Gu, Z., & Hechter, R. C. (2025). Chronic opioid use and incident opioid use disorders in survivors of adolescent and young adult cancer after cancer treatment. Cancer. https://doi.org/10.1002/cncr.35866
Vancouver
Chao CR, Zhou H, Shalman DM, Pak KJ, Armenian S, Xu L, et al. Chronic opioid use and incident opioid use disorders in survivors of adolescent and young adult cancer after cancer treatment. Cancer. 2025. doi:10.1002/cncr.35866
BibTeX
@article{Chao2025,
author = {Chao, Chun R and Zhou, Hui and Shalman, Dov M and Pak, Katherine J and Armenian, Saro and Xu, Lanfang and Gu, Zheng and Hechter, Rulin C},
title = {Chronic opioid use and incident opioid use disorders in survivors of adolescent and young adult cancer after cancer treatment},
journal = {Cancer},
year = {2025},
doi = {10.1002/cncr.35866}
}
EUVIMED